Pacific Biosciences
PACB
Market cap $430M

1.57 USD

-0.03

1.88%

At close Nov 18, 4:00 PM EST

After hours

1.59

+0.02

1.27%

1 day

-1.88%

5 days

-35.66%

1 month

-20.71%

3 months

-1.88%

6 months

-18.23%

Year to date

-83.63%

1 year

-81.70%

5 years

-66.16%

10 years

-77.47%

About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Employees: 796

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]

17% more capital invested

Capital invested by funds: $336M [Q2] → $394M (+$58.1M) [Q3]

9% less call options, than puts

Call options by funds: $3.32M | Put options by funds: $3.63M

3% less funds holding

Funds holding: 225 [Q2] → 219 (-6) [Q3]

5.09% less ownership

Funds ownership: 90.1% [Q2] → 85.01% (-5.09%) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 76

21% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 29

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

27%

upside

Avg. target

$4.38

179%

upside

High target

$7

346%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

UBS John Sourbeer 0 / 0 met price target	27%upside $2	Neutral Downgraded	11 Nov 2024
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target	282%upside $6	Sector Outperform Maintained	11 Nov 2024
Piper Sandler David Westenberg 57% 1-year accuracy 12 / 21 met price target	59%upside $2.50	Neutral Maintained	11 Nov 2024
Scotiabank Sung Ji Nam 50% 1-year accuracy 10 / 20 met price target	346%upside $7	Sector Outperform Maintained	28 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 29 articles about PACB published over the past 30 days

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 million missed analyst estimates, with SG&A expenses surpassing total revenue and gross profit margins remaining low at 28%. Pacific Biosciences has made significant cuts in R&D, which may harm long-term growth given the rapid technological advancements in the genomic market.

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The rock star money manager is starting to roll with the rallying market.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

PacBio to Present at Upcoming Investor Conferences

Zacks Investment Research

PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y

PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.

PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y

Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian Henry - President and Chief Executive Officer Susan Kim - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Kyle Nixon - Canaccord Mason Carrico - Stephens Dan Brennan - TD Cowen Jack Meehan - Nephron Research Subbu Nambi - Guggenheim Securities Madeline Mollman - Wolfe Research Operator Good day and welcome to the PacBio Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript

Zacks Investment Research

Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago.

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's remaining outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which PacBio will (i) issue $200 million principal amount of its 1.50% Convertible Senior Notes due 2029 (the “New Notes”), (ii) issue 20,451,570 shares (the “Shares”) of PacBio's common stock (“common stock”), and (iii) make a cash payment in the amount of $50 million (the “Cash Consideration”) in exchange for $459 million principal amount of the 2028 Notes (the “Exchange Transaction”), in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder. The Exchange Transaction is expected to close on or about November 21, 2024, subject to customary closing conditions.

PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory

PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop

The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud

LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud

See News Rankings

Charts implemented using Lightweight Charts™